Chronic Atrial and Intestinal Dysrhythmia (CAID) syndrome is a rare autosomal recessive cohesinopathy classically defined by sick sinus syndrome and chronic intestinal pseudo-obstruction. Emerging evidence suggested an association between CAID and cerebral small vessel disease (CSVD). The investigators aimed to characterize the neurological manifestations and the neuroimaging spectrum of CSVD in a genetically confirmed CAID cohort.
The study was a cross-sectional, retrospective analysis of 16 French-Canadian individuals with genetically confirmed CAID syndrome. The median age at last evaluation was 34 years (range, 19–60), and 62.5% of the cohort were women. All patients underwent comprehensive neurological assessment; brain MRI was available for 14 patients. Neuroimaging markers of CSVD were evaluated by an expert neuroradiologist according to the STRIVE-2 criteria.
Neurological manifestations observed included migraines in 44.4% of patients and mild cerebellar signs in 16.7%. Clinically manifest cerebrovascular events—either ischemic or hemorrhagic—occurred in 12.5% of the cohort. The report emphasizes that neurological involvement in CAID is heterogeneous but includes both symptomatic and radiological features of small vessel disease.
Brain MRI studies were systematically reviewed using STRIVE-2 criteria to identify and classify CSVD markers. The analysis recorded white matter hyperintensities, lacunes, and cerebral microbleeds, and documented lesion distribution across deep, lobar, and infratentorial compartments.
MRI abnormalities were frequent in the imaged patients: white matter hyperintensities were seen in 92.9% (13/14), lacunes in 50.0% (7/14), and cerebral microbleeds in 85.7% (12/14). Notably, five patients had innumerable microbleeds. These findings indicate early and widespread parenchymal small vessel injury in this CAID cohort despite a relatively young median age.
Lesions affected deep, lobar, and infratentorial regions. The authors highlight a distinct cerebellar predominance, with infratentorial involvement seen in most affected patients and cerebellar lesions present in 11 of 12 patients with microbleeds or infratentorial disease (91.7%). This regional pattern is emphasized as a distinguishing neuroimaging feature of CAID-associated CSVD.
Despite the young age distribution, moderate-to-severe CSVD was common within the cohort. The reported median SVD score was 1.5 with an interquartile range of 0–4, indicating a burden of small vessel disease that may be clinically consequential even in early adulthood for some patients.
Patients who exhibited countless microbleeds were older than those with discrete lesions (mean 46.2 vs. 31.2 years). This difference reached statistical significance in the cohort (p = 0.043), suggesting a relationship between age and microbleed burden within CAID.
CAID patients frequently have congenital cardiac disease and cardiac rhythm disturbances, including atrial fibrillation and sick sinus syndrome. These coexisting cardiac conditions create a dual risk profile: thromboembolic ischemic risk from arrhythmia and heightened hemorrhagic risk from abundant cerebral microbleeds. Management of atrial fibrillation in this series required individualized strategies; the authors report cases where left atrial appendage closure was employed to balance ischemic and hemorrhagic risks. The findings support careful multidisciplinary decision-making when considering antithrombotic therapy in CAID.
The authors interpret CAID syndrome as a novel monogenic cause of CSVD, characterized by early, extensive cerebral microbleeds with mixed anatomic distribution and a distinctive cerebellar predominance. They recommend systematic neurological evaluation and brain MRI for patients with CAID, particularly before initiating antithrombotic or anticoagulant therapy, given the combined ischemic and hemorrhagic risks. The work underscores the need to individualize stroke prevention strategies in this population.
The study received ethics approval from the CHU Sainte-Justine and CHU de Québec committees (MP-21-2006-107, F2-29921). The authors declared no competing interests. Anonymized clinical and derived neuroimaging data are available from the corresponding author upon reasonable request, subject to privacy and ethical restrictions.